Widespread Implementation of Long-Acting PrEP for HIV May Be Stifled By High Price Tag, Say Researchers
Pharmacy Times
DECEMBER 12, 2022
Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.
49 
Let's personalize your content